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Abstract
Background: in chronic kidney disease (CKD), hypertension is associated with poor outcomes at ages <70 years. At older
ages, this association is unclear. We tested 10-year mortality and cardiovascular outcomes by clinical systolic blood pressure
(SBP) in older CKD Stages 3 and 4 patients without diabetes or proteinuria.
Methods: retrospective cohort in population representative primary care electronic medical records linked to hospital data
from the UK. CKD staged by CKD-EPI equation (≥2 creatinine measurements ≥90 days apart). SBPs were 3-year medians
before baseline, with mean follow-up 5.7 years. Cox competing models accounted for mortality.
Results: about 158,713 subjects with CKD3 and 6,611 with CKD4 met inclusion criteria. Mortality increased with increas-
ing CKD stage in all subjects aged >60. In the 70 plus group with SBPs 140–169 mmHg, there was no increase in mortality,
versus SBP 130–139. Similarly, SBPs 140–169 mmHg were not associated with increased incident heart failure, stroke or
myocardial infarctions. SBPs <120 mmHg were associated with increased mortality and cardiovascular risk. At ages 60–69,
there was increased mortality at SBP <120 and SBP >150 mmHg.
Results were little altered after excluding those with declining SBPs during 5 years before baseline, or for longer-term out-
comes (5–10 years after baseline).
Conclusions: in older primary care patients, CKD3 or 4 was the dominant outcome predictor. SBP 140–169 mmHg having
little additional predictive value, <120 mmHg was associated with increased mortality. Prospective studies of representative
older adults with CKD are required to establish optimum BP targets.
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Key points
• This study examined a large sample of 158,713 older adults with chronic kidney disease (CKD) 3 or 4, free of diabetes or proteinuria.
• Systolic BPs substantially higher than current targets did not increase mortality or incident cardiovascular outcomes.
• Systolic BPs <120 and 120–129 mmHg were associated with excess mortality.
• Results suggest renal stage is a better predictor of clinical outcomes than BP in older adults.
• Research is required to establish evidence-based BP targets specific to older patients with Stages 3 and 4 CKD.
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Introduction
Chronic kidney disease (CKD) is common in older adults
and is an established risk factor for mortality and cardiovas-
cular events [1]. Kidney disease: improving global outcomes
(KDIGO) described the grading system used internationally
for CKD, with Grade 3 representing moderate impairment,
Grade 4 severe impairment and Grade 5 kidney failure [2].
Global estimates of CKD3–5 prevalence for adults over 70
years range from 14.1% in the Netherlands to 56.6% in
Ireland, higher in women [3, 4]. CKD and hypertension
frequently co-exist and independently increase the risk of
cardiovascular outcomes [1, 5, 6]. Blood pressure (BP)
management is a key aspect of CKD clinical care. However,
studies incorporated into guidelines on BP in CKD largely
exclude adults older than 70 years [7], despite comprising
over half of the CKD population [8].
Debate continues about safe levels of BP reduction in
older adults. Until recently, the consensus internationally for
older adults with CKD without diabetes or significant pro-
teinuria was to control BP to a target of <140/90 mmHg
[7, 9, 10]. CKD guidelines do not specifically recommend
adjustments for BP management in older adults. The
recently published American College of Cardiology/American
Heart Association hypertension guidelines [11] suggest a
‘team-based approach to risk/benefit’ in older adults, but
currently BP-associated prognosis in older adults with
moderate to severe CKD is not known [6].
Weiss et al. [12] investigated Systolic BP (SBP) and mor-
tality in older adults with CKD and found that the relation-
ship varied with age: a U-shaped mortality curve at age
65–70, but no increased mortality in adults aged over 70
years at SBP >140 mmHg, compared to 131–140 mmHg,
and higher mortality at SBP <130 mmHg. However, the
study did not report cardiovascular outcomes or allow for
BP dynamics. We have recently shown BPs decline from 14
to 18 years prior to death [13], potentially biasing observa-
tional studies by confusing cause and effect.
The Systolic Blood Pressure Intervention Trial (SPRINT) [14]
enrolled adults with high cardiovascular risks taking antihyperten-
sive medication with SBP between 130 and 139 mmHg,
and studied the effect of reducing SBP to a target of
<120 mmHg. In a predefined CKD sub-analysis (mean
age 71.9 with 43.9% aged ≥75), the composite cardiovascular
trended lower in the intervention group, but did not reach sig-
nificance (hazard ratio (HR) 0.81; 95% CI, 0.63–1.05), and
intervention group overall mortality outcome was lower (HR,
0.72; 95% CI, 0.53–0.99). Importantly, there was no evidence
of effect modification comparing those with and without
CKD. Although the SPRINT trial clearly provides more
robust evidence than observational studies, it does have limita-
tions: e.g. those with cognitive impairment, unable to stand or
in a nursing home were excluded; CKD in SPRINT was rela-
tively mild Grade 3 CKD with a mean estimated Glomerular
Filtration Rate (eGFR) of 47.4ml/min per 1.73m2; 11% with-
drew consent or were lost to follow-up, and separate results
for the 75 plus group were not reported. Also, the trial was
stopped after a 3.3 years median follow-up due to evidence of
overall benefit across the intervention group, with ascertain-
ment of longer-term outcomes therefore necessarily remaining
unmeasured.
In this observational analysis, we aimed to estimate
mortality and cardiovascular outcomes in a representative,
population-based cohort aged over 60 years (for compari-
son with existing studies), with CKD3 and 4, according to
SBP, followed for up to 10 years. We used large-scale data
from the Clinical Practice Research Datalink (CPRD) of
primary care medical records. CPRD includes routine clin-
ical measurements of creatinine and BP linked to clinical
records. CKD3 and 4 were the focus population of this
study to encompass older adults with clinically significant
renal impairment but predominantly cared for in primary
care.
Methods
Data source
We used data from the Clinical Practice Research Datalink
(CPRD), which provides anonymised primary care data for
over 11.3 million patients from 674 UK community prac-
tices for health research [8]. The CPRD is linked to hospital
episode statistics (HES) and death certification. Ethical
approval was granted by the Independent Scientific Advisory
Committee for UK Medicines and Healthcare Products
Regulatory Agency database research (ISAC) under protocol
number 14_135 and 14_135RA. The CPRD is shown to be
representative of the UK population for age, sex and ethnicity
[15], and to have good external validity for CKD [16] and
cardiovascular disease [17]. The CPRD obtained Multiple
Research Ethics Committee approval (05/MRE04/87) to
undertake purely observational studies. CPRD is also cov-
ered by NIGB-ECC approval ECC 5–05 (a) 2012.
Sample selection
Adults aged over 60 years were included, with age categor-
ies 60–70 years, for comparison with previous studies, and
over 70 years. The index date was the date when all selec-
tion criteria were met, between 1 January 2000 and 14
November 2014.
We focussed on CKD3 and 4, excluding CKD 5 (eGFR
<15 ml/min/1.73 m2) who have a different risk profile
[8, 18], and are largely managed in secondary care. We
excluded previous renal transplant and polycystic kidney
disease due to mechanisms that may alter relationship with
BP. We excluded pre-existing diabetes, as defined by the
Quality and Outcomes Framework business rules at index
date [19] which are used to identify adults within primary
care with clinically diagnosed diabetes. We also excluded
significant proteinuria (>30 mg/mmol Albumin Creatinine
Ratio or equivalent in recorded laboratory values or medical
read codes for proteinuria), as these groups have different
risk profiles and are subject to different clinical guidelines.
J. A. Masoli et al.
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In order to minimise reverse causation, we excluded preva-
lent heart failure, dementia, cancer and those within 6
months of death, who would have increased mortality and
potentially declining BP trends.
CKD and blood pressure measures
The eGFR was calculated from creatinine, based on the
CKD-Epidemiology Collaboration (CKD-EPI) equation [20],
shown to be valid in older adults [21]. The CKD category
was derived from eGFR according to KDIGO definitions
[2]. Two eGFR measurements in the same CKD category
were required over 90 days apart, as per clinical guidelines
[7], within 3 years prior to index date.
BP values were from routine clinical measurements. To
minimise potential bias due to atypical values obtained dur-
ing acute illness, we used median BP from the 3 years prior
to index date. The main analysis focuses on those without
declining BP in the 5 years prior to index date, as we previ-
ously described declining BP trajectories over 10 years prior
to death [13].
Outcomes
Follow-up was for a maximum of 10 years, until death or
study end date of 14 November 2014.
The outcomes of interest were all-cause mortality and
incident cardiovascular disease: ischaemic stroke (stroke),
myocardial infarction or cardiac revascularisation procedure
(MIP) and heart failure. All-cause mortality was established
from HES codes and office of national statistics (ONS).
Incident cases of stroke, MIP, and heart failure were
established from HES and primary care Read Codes spe-
cific to the conditions. We used HES for stroke outcomes
to increase specificity for ischaemic stroke [22]. In addition,
for MIP we used the Office of Population Censuses and
Surveys Classification of Interventions and Procedures ver-
sion 4 (OPCS) [23] to increase yield of clinically significant
coronary artery disease by including coronary angioplasty
and coronary artery bypass graft procedures.
Covariates
Sex, age, year of index date (for clinical practice changes),
social deprivation status, smoking status, BMI category and
alcohol status were adjusted for in the main study models
(see Appendix 1, available at Age and Ageing online). These
covariates were adjusted for in mortality and cardiovascular
analyses.
Sensitivity analyses
We investigated the effect of diastolic BP on outcomes sep-
arately, with the same adjustments and methods as for SBP.
We conducted overall subgroup analyses by sex and for
those with declining BPs. To address possible reverse caus-
ation, for example from clinically undiagnosed heart failure,
we performed a sensitivity analysis censoring the first 5
years of follow-up, which also provided information about
longer-term outcomes given that existing studies have been
largely restricted to <4 years [7, 24]. In addition, we per-
formed a sensitivity analysis stratifying by Charlson comorbid-
ity index to check whether results were different according to
comorbid status [25].
Statistical analysis
Statistical analysis was performed using Stata v14.1.
We used Cox proportional hazards models to estimate
associations between CKD grade, baseline SBP and all-
cause mortality and Fine and Gray competing risk models
[26] for cardiovascular outcomes, with all-cause mortality as
the competing risk.
Analyses were stratified according to age group (60–70
and 70+) and CKD stage (3 or 4). The comparison group
was attained SBP 130–139 mmHg, in keeping with current
international guidelines [7, 10, 27].
Missing data
Clinical information within the study was felt likely to be
missing not at random. Cohort selection was determined by
laboratory identification of CKD and BPs collected by rou-
tine clinical measurements. Therefore, those with less
healthcare seeking behaviour may be under-represented in
this study. However, in the UK over 98% of the population
are registered with a primary healthcare provider and con-
sultations are free of charge [28].
Loss to follow-up in this routinely collected dataset is
possible for those who transfer out of the CPRD participat-
ing practices prior to the end of follow-up or death, but
mortality outcomes were obtained from national health cer-
tification and so are near complete. Loss to follow-up other
than mortality can occur on change of practice and there-
fore is likely to be a combination of those who move into a
formal care setting outside their previous area and those
who are healthy and relocate. Those transferred out of the
practice were censored.
Results
About 165,324 subjects met inclusion criteria for this ana-
lysis, 158,713 (96%) with CKD3 and 6,611 with CKD4.
The mean age was 76 years (range 60–107), and 63% were
women. Baseline characteristics and incident outcomes are
summarised in Table 1. Maximum follow-up was 10 years
(mean = 5.7 years, SD 3.12). During the follow-up period
50,715 (30.7%) participants died, 8,753 (5.2%) had incident
MIP, 13,864 (8.4%) stroke and 10,602 (6.4%) heart failure.
Survival by CKD stage
Mortality was substantially higher for CKD4 compared
with CKD3 (see Appendix 2, available at Age and Ageing
online), in both age-groups. All studied cardiovascular
Outcomes of raised blood pressures in older adults
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outcomes were increased in CKD4 compared to CKD3
(see Appendix 3, available at Age and Ageing online).
Mortality outcomes by SBP
With baseline CKD3 (see Figure 1), HRs of mortality were
U-shaped in adults aged 60–70, with increased mortality at
SBP >150 mmHg compared with SBP 130–139 mmHg.
However, for over 70 years with CKD3 the mortality HR
did not increase until SBP ≥180 mmHg. All with CKD3 at
baseline had increased mortality with SBP <120 mmHg and
120–129 mmHg. With CKD4 at baseline, those aged over
70 again had no significant increase in mortality risk with
SBPs over the current target from 140–170 mmHg.
Cardiovascular outcomes by SBP
In adults over 70 with CKD3 or 4, the stroke HR did not
increase (Table 2), even with SBPs of 140–180 mmHg: sig-
nificantly higher than recommended target, while for 60–70
year olds there was a trend to increased hazards at
increased SBP. SBPs up to 160 mmHg were not associated
with statistically significant increased risk of incident MIP in
adults over 70 with either CKD3 or 4 at baseline.
The HR for incident heart failure was raised in SBP cat-
egories <120 and 120–129 mmHg in adults over 70 with
CKD3 or 4, but there was no increased risk at SBPs over
the target BP of 130–139 mmHg and up to 180 mmHg.
Sensitivity analyses
Sensitivity analyses are presented in Appendices 5–12, avail-
able at Age and Ageing online.
Diastolic BP (DBP) of <70 mmHg was associated with
increased mortality in adults 60–70 years and over 70 with
CKD3 and 60–70 with CKD4 (see Appendix 5, available at
Age and Ageing online). There was no significant difference
in mortality HR between the 80–89 and 90–99 mmHg
in adults 60–70 years and over 70 with CKD3 or 4.
Cardiovascular outcomes with DBP varied with outcome,
CKD and age group (see Appendix 6, available at Age and
Ageing online).
Mortality outcomes were similar for men and women
(see Appendix 7, available at Age and Ageing online).
Elevated SBP had a higher HR for stroke outcomes in men
than women (see Appendix 8, available at Age and Ageing
online) with both CKD3 and 4, while results for MIP and
heart failure were similar for men and women.
Analysis of longer-term outcomes (5–10 years) pro-
duced similar results to the main analysis (see Appendices 9
and 10, available at Age and Ageing online), as did declining
BP trajectories (see Appendices 11 and 12, available at Age
and Ageing online).
Consistent results were produced across categories of
Charlson comorbidity index (0, 1–2, 3–4 and ≥5) (see
Appendix 13, available at Age and Ageing online).
Discussion
Previous studies have provided clear evidence that both
CKD stage [29] and BP lowering [24, 30] are predictive of
outcomes in adults aged up to 70 years old, but evidence at
older ages was less clear. In this large-scale study of older
primary care patients with CKD3 and 4 (but free of dia-
betes or proteinuria), we found that in subjects aged 70+,
routine clinical SBPs 140–169mmHg were not associated
with excess mortality or incident cardiovascular morbidity,
compared to achieving SBPs of 130–140mmHg. Conversely,
SBPs of <120mmHg were associated with worse prognosis.
Our findings are consistent with El Nahas et al. [6].,
who argued the high prevalence of CKD in older adults
represents accumulation of cardiovascular disease and ath-
erosclerosis, diffuse ‘cardio-kidney damage’. This cumulative
end-organ damage appears more influential on cardiovascular
and mortality outcomes than the current BP.
The changing relationship between SBP and mortality in
older adults with CKD was previously described by Weiss
et al. [12]. who reported analysis of SBP and all-cause mor-
tality in 21,015 adults over 65 from Northwest United
States, with 3.53 years median follow-up. Our mortality
results are consistent with this analysis, which found that
all-cause mortality was elevated with SBP >140 mmHg for
adults 65–70, but in adults over 70 all-cause mortality was
no different with SBP >140 mmHg compared to the refer-
ence group. Our study is a major extension of this work.
Weiss et al. [12] did not evaluate cardiovascular outcomes
and included some conditions at baseline that may cause
reverse causation, such as diabetes. However, they report a
sensitivity analysis excluding heart failure produced similar
results.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Characteristics of the sample by CKD grade at
baseline
CKD3 CKD4
Overall
N (%) 158,713 (96) 6,611 (4)
Age in years, mean (SD) 76.5 (8.4) 82.0 (9.2)
Female (%) 100,518 (63) 4,112 (62)
Median SBP mmHg (SD) 145 (15.4) 146 (17.4)
Median DBP mmHg (SD) 80 (7.9) 80 (8.6)
Mean GFR ml/min per 1.73 m2 (SD) 48.8 (7.5) 23.9 (4.0)
Incident MI, N (%) 8,317 (5) 436 (7)
Incident IS, N (%) 13,265 (8) 599 (9)
Incident HF, N (%) 9,961 (6) 641 (10)
Died, N (%) 46, 886 (29) 3,829 (58)
Over 70 years
N (%) 66, 974 (97) 1,940 (3)
Female (%) 41, 162 (61) 1, 151 (59)
Median SBP mmHg (SD) 145 (15.2) 148 (17.3)
Median DBP mmHg (SD) 80 (7.7) 76 (4.4)
Mean GFR ml/min per 1.73 m2 (SD) 48.0 (7.5) 24.1 (3.9)
Incident MI, N (%) 3,828 (6) 139 (7)
Incident IS, N (%) 5, 950 (9) 191 (10)
Incident HF, N (%) 4,376 (7) 213 (10)
Death, N (%) 17,709 (26) 3,798 (55)
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Figure 1. Adjusted associations (Hazard ratios) of systolic blood pressure and mortality in older adults with CKD3 and CKD4, stratified by age group.
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We described the SPRINT randomised trial [14] CKD
sub-study in our introduction. Randomised trails provide
robust evidence on treatment effects and cannot be directly
compared to our observational results which focus on
prognosis. The SPRINT CKD recruited patient group dif-
fered from the group we studied: for example, the all-cause
death rate in the SPRINT CKD sub-study control group
(mean age 71) was 2.21% per year, but in our sample
(mean age 76) the death rate was 5.38% per year (95%CI
5.34%–5.42%, n = 50,715/165,324 over 5.7 year mean
follow-up, 5.2% in CKD3, 10.2% in CKD4). The results of
SPRINT are clearly more robust than observational studies,
but questions do remain for the routine long-term care of
the full range of typical older groups managed in primary
care, who often continue with antihypertensive medications
for many years. As our subjects represent whole older popula-
tions (virtually all older people are registered with primary
care, including those with cognitive impairments and in institu-
tional settings) with practically complete follow-up through the
national hospital and death certification systems, our estimates
of prognosis may be informative for developing treatment
approaches for the wider older population.
A systematic review and meta-analysis by Malhotra et al.
[24] investigated mortality outcomes in adults with
CKD3–5 according to intensity of BP control. Included
trials decreased mean SBP to 132 mmHg in the intensive
arm and to 140 mmHg in the less intensive arms, with
median follow-up of 3.6 years and a mean difference in
SBP of 10 mmHg between the two groups. The overall
odds ratio for all-cause mortality was reported as 0.86 (95%
CI, 0.76–0.97; P = 0.01) for more intensive versus less
intensive BP control. While some of the included studies
were focussed on older adults (e.g. the Hypertension in the
Very Elderly Trial (HYVET) [31]), outcomes for older
adults were not reported separately.
Our study has a number of key strengths. We report the
results of the largest cohort study on BP that has been con-
ducted in older adults with established CKD. A particular
strength of our analysis is the representative nature of the
cohort for older adults in the general population. We have
included a substantial median follow-up (5.7 years, max-
imum 10). We have accounted for BP dynamics and shown
that results are similar with stable or declining BPs, as well
as for long-term and short-term follow-up.
There are inevitably limitations of our analyses. This is
prospective observational analysis using existing data—the
exposure status was collected prior to the outcome data,
however it was not a controlled trial and could therefore be
subject to unmeasured confounding. We have adjusted for
relevant measured potential confounding factors and add-
itionally conducted sensitivity analyses. Data on proteinuria
were only available for a limited proportion of those with
CKD3 and 4, but those with significant proteinuria or dia-
betes were excluded as these groups are subject to different
clinical guidelines and should be considered separately.
An important difference with trials such as SPRINT is
that our BP measurements were from clinical routine data,
which can provide higher BP measures than BPs taken
under research conditions [32]. However, in our analyses
we used median BP recorded over 3-year periods prior to
index date. In addition to giving stable overall estimates, 3-
year mean BPs should have removed the effects of atypical
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Associations (Hazard ratios) of systolic blood pressure and cardiovascular outcomes in older adults with CKD3
and 4, stratified by age group
Systolic blood pressure (mmHg) Age 60–70 years Age > 70 years
Myocardial infarction
HR (95% Confidence
interval)
Heart failure HR
(95% CI)
Stroke HR
(95% CI)
Myocardial infarction
or procedure HR
(95% CI)
Heart failure HR
(95% CI)
Stroke HR
(95% CI)
Chronic kidney disease 3 at baseline
<120 0.86 (0.64–1.16) 1.90 (1.50–2.40)** 0.98 (0.76–1.27) 1.38 (1.13–1.68)** 1.66 (1.40–1.96)** 0.96 (0.80–1.15)
120–129 0.96 (0.78–1.17) 1.21 (0.99–1.48) 0.99 (0.82–1.19) 1.04 (0.89–1.21) 1.21 (1.07–1.38)** 0.93 (0.82–1.05)
130–139 (reference category) 1 1 1 1 1 1
140–149 0.84 (0.72–0.98)* 0.91 (0.78–1.07) 0.97 (0.85–1.11) 0.99 (0.89–1.10) 0.90 (0.82–0.99)* 0.99 (0.91–1.07)
150–159 1.04 (0.88–1.22) 0.80 (0.66–0.95)* 1.11 (0.96–1.28) 0.97 (0.87–1.09) 0.83 (0.75–0.92)** 0.95 (0.87–1.03)
160–169 1.03 (0.85–1.24) 0.98 (0.81–1.20) 1.19 (1.00–1.40)* 1.12 (0.99–1.26) 0.86 (0.77–0.97)* 0.97 (0.88–1.06)
170–179 0.91 (0.68–1.22) 1.04 (0.79–1.38) 1.23 (0.97–1.56) 1.06 (0.90–1.23) 0.96 (0.83–1.11) 1.00 (0.88–1.13)
≥180 1.13 (0.77–1.67) 1.26 (0.87–1.82) 1.74 (1.30–2.32)** 1.40 (1.16–1.69)** 1.18 (0.99–1.40) 1.28 (1.10–1.49)**
Chronic kidney disease 4 at baseline
<120 Insufficient data 2.08 (0.76–5.71) 2.76 (0.82–9.27) 1.27 (0.41–3.89) 1.78 (0.77–4.12) 1.09 (0.45–2.66)
120–129 1.37 (0.45–4.14) 0.38 (0.09–1.68) 1.40 (0.47–4.2) 1.11 (0.47–2.67) 1.83 (0.95–3.51) 1.08 (0.57–2.05)
130–139 (reference category) 1 1 1 1 1 1
140–149 1.34 (0.59–3.04) 0.68 (0.32–1.45) 1.48 (0.68–3.22) 0.98 (0.51–1.86) 1.10 (0.64–1.90) 0.73 (0.43–1.24)
150–159 1.96 (0.86–4.48) 1.18 (0.57–2.45) 2.16 (1.00–4.68) 0.83 (0.42–1.63) 1.27 (0.73–2.19) 0.86 (0.51–1.45)
160–169 1.64 (0.57–4.69) 1.22 (0.52–2.86) 2.01 (0.82–4.93) 1.21 (0.61–2.39) 1.13 (0.62–2.05) 1.03 (0.59–1.79)
170–179 0.39 (0.05–3.23) 1.48 (0.58–3.80) 0.72 (0.15–3.49) 1.63 (0.80–3.33) 1.69 (0.93–3.08) 0.84 (0.44–1.60)
≥180 3.68 (1.45–9.35) 0.70 (0.16–3.08) 2.46 (0.82–7.34) 1.61 (0.67–3.84) 1.05 (0.45–2.45) 1.05 (0.48–2.27)
*P value <0.05; **P value <0.01.
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values for each patient, for example those obtained during
acute illness. Finally, the BP measures were those that fam-
ily physicians were using to guide clinical decisions, and
therefore have validity in estimating prognosis in typical
care settings. Our results that, e.g. we observed no increase
mortality in the 70 plus group with SBPs from 160 to
169 mmHg (versus SBP 130–139) appears difficult to
explain away with the usually modestly lower SBPs in both
the high SBP group and the comparison category that
might have been measured in research settings.
The majority of the cohort had CKD3, leading to small
sample sizes within SBP categories of CKD4 and wide con-
fidence intervals. More work is required into prognosis by
attained SBP in older adults with CKD3 and 4 and signifi-
cant proteinuria or co-existing diabetes.
Although we have tried to minimise confounding,
residual confounding is always possible in observational
studies, and our results should be regarded as estimates of
observed prognosis rather than necessarily being directly
driven only by antihypertensive medication effects. The evi-
dence presented, however, suggests the need for further
work, preferably including randomised trials, to provide a
stronger evidence base for current BP targets in older
CKD patients without diabetes.
Conclusion
This large-scale analysis of attained SBP in a representative
cohort of older adults with CKD3 and 4 provides further
evidence that older adults have different prognoses from
relatively younger or healthier adults. We found that SBP
up to 169 mmHg were not associated with increased mor-
tality or heart failure in adults over 70 compared with BP
130–140 mmHg, while SBP of 120–129 mmHg and
<120 mmHg were associated with worse prognosis.
Approaches to clinical management of SBP in older patients
with CKD should not necessarily be based on extrapolating
findings from younger groups. Further prospective studies,
preferably including randomised trails, are required in repre-
sentative older adults to establish optimum BP targets in old-
er adults with CKD.
Supplementary data mentioned in the text are available to
subscribers in Age and Ageing online.
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